OK Biotech CoTPE:4155 61 Days Payable is 45.63 as of Dec. 2025, which is 36% below its 10-year median of 71.70. GuruFocus rates TPE:4155 with a GF Score™ of 61/100 and a GF Value™ of NT$27.26 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 795 Medical Devices & Instruments companies, OK Biotech Co ranks worse than 66.92% on this metric.
The historical rank and industry rank for OK Biotech Co's Days Payable or its related term are showing as below:
TPE:4155'
s Days Payable Range Over the Past 10 Years
Min: 49.49 Med: 71.7 Max: 81.38
Current: 49.49
During the past 13 years, OK Biotech Co's highest Days Payable was 81.38. The lowest was 49.49. And the median was 71.70.
TPE:4155's Days Payable is ranked worse than 66.92% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TPE:4155: 49.49
OK Biotech Co's Days Payable
declined
from Dec. 2024 (61.85) to Dec. 2025 (45.63).
It may suggest that OK Biotech Coaccelerated paying its suppliers.
OK Biotech Co Days Payable Related Terms
OK Biotech Co Days Payable Historical Data
* Premium members only.
The historical data trend for OK Biotech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4155 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, OK Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
OK Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co (TPE:4155) has a Days Payable of 45.63 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OK Biotech Co and its competitors. This is 36% below median its historical median of 71.70. Over the past decade, OK Biotech Co's Days Payable has ranged from 49.49 to 81.38. According to the industry distribution chart, OK Biotech Co ranks #532 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 66.9%.
Is OK Biotech Co's Days Payable too high?
OK Biotech Co's current Days Payable of 45.63 is 36% below median its 10-year median of 71.70. Over the past 10 years, this metric has ranged from a low of 49.49 to a high of 81.38. The Medical Devices & Instruments industry median Days Payable is 68.07. OK Biotech Co's value of 45.63 is 33% below this industry median. Based on the distribution chart, OK Biotech Co ranks #532 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, OK Biotech Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #532 out of 795 companies for Days Payable. This places OK Biotech Co in the lower half of its industry. The industry median Days Payable is 68.07. OK Biotech Co's value of 45.63 is 33% below this benchmark. Historically, OK Biotech Co's own Days Payable has ranged from 49.49 to 81.38 over the past decade. While the company's 10-year median is 71.70 vs. the industry median of 68.07, OK Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current Days Payable of 45.63 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current Days Payable is 45.63, which is 36% below median its own 10-year median of 71.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$27.26, compared to a current price of NT$15.30 — trading 43.9% below its estimated fair value. The current Days Payable is 45.63, which is 36% below median its 10-year median of 71.70 and 33% below the Medical Devices & Instruments industry median of 68.07. OK Biotech Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current Days Payable is 45.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$15.30 is trading 43.9% below its estimated GF Value™ of NT$27.26.
GuruFocus considers OK Biotech Co to be Possible Value Trap.
Key valuation signals for TPE:4155:
Days Payable: 45.63 (36% below median its 10-year median of 71.70)
GF Value™: NT$27.26 vs. price of NT$15.30 (43.9% below fair value)
Industry Position: 33% below the Medical Devices & Instruments median (#532 of 795)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
61GF Score
Get the complete analysis for TPE:4155
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
